Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2010

View Archived Issues

New Pim kinase inhibitor ARRY-770 reduces airway hyperresponsiveness in mice

Adalimumab improves quality of life in Crohn's disease patients

Evotec Neurosciences claims bradykinin B1 receptor antagonists

CETP gene polymorphism linked to reduced risk for dementia

Topical WBI-1001 improves atopic dermatitis in double-blind trial

Roche discovers new GlyT-1 inhibitors

Merck KGaA discloses novel tyrosine kinase inhibitors

Bayer Schering claims new adenosine A1 receptor antagonists

Sanofi-aventis patents new cannabinoid CB1 receptor antagonists

NIAID awards PDS phase II grant for HPV cancer vaccine

Ark withdraws Cerepro MAA after EMA's request for further trial in malignant glioma

Vernalis terminates agreement with PCH and regains rights to frovatriptan

Biotie and Pfizer to end discovery phase of development of PDE10 inhibitors for schizophrenia

Stanford University requests data from Favrille's cancer vaccine trials

Ischemix begins phase IIa CMX-2043 trial in ischemia reperfusion injury

Ista receives action date for FDA review of XiDay sNDA

Chimerix begins phase II CMX-001 study in CMV-seropositive stem cell transplant recipients

Bristol-Myers and AstraZeneca begin phase IV Onglyza trial

Enrollment begins in phase IIb trial of NTx-265 in acute ischemic stroke

mtm laboratories launches cervical cancer test CINtec Plus in Europe

Omthera to advance Epanova for hypertriglyceridemia

Celltrion develops broad-spectrum human monoclonal antibodies against influenza

Omeros licenses Asubio's PDE7 inhibitors for movement disorders

Harvard and Dana-Farber grant Acetylon exclusive license to HDAC inhibitor discovery platform

Abbott and GSK to develop molecular diagnostic test for skin cancer treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...